Although excision repair cross-complementing group 6 (ERCC6) has been reported to be associated with lung cancer risk, the specific roles of ERCC6 in non-small cell lung cancer (NSCLC) progression are inadequately studied. Thus, this study aimed to examine the potential functions of ERCC6 in NSCLC. The expression of ERCC6 in NSCLC was analyzed by immunohistochemical staining and quantitative PCR. Celigo cell count, colony formation, flow cytometry, wound-healing, and transwell assays were used to evaluate the effects of ERCC6 knockdown on the proliferation, apoptosis, and migration of NSCLC cells. The effect of ERCC6 knockdown on tumor-forming ability of NSCLC cells was estimated by establishing xenograft model. ERCC6 was highly expressed in NSCLC tumor tissues and cell lines, and high ERCC6 expression was significantly associated with poor overall survival. Additionally, ERCC6 knockdown significantly suppressed cell proliferation, colony formation and migration, while accelerated cell apoptosis of NSCLC cells in vitro. Moreover, ERCC6 knockdown inhibited tumor growth in vivo. Further studies verified that ERCC6 knockdown attenuated the expression levels of Bcl-w, CCND1, and c-Myc. Altogether, these data unveil a major role of ERCC6 in the progression of NSCLC, and ERCC6 is expected to become a novel therapeutic target for NSCLC treatment.

中文翻译：

---

ERCC6在非小细胞肺癌的进展中起促进作用。

尽管切除修复交叉互补组 6 (ERCC6) 已被报道与肺癌风险相关，但 ERCC6 在非小细胞肺癌 (NSCLC) 进展中的具体作用研究不足。因此，本研究旨在检查 ERCC6 在 NSCLC 中的潜在功能。通过免疫组织化学染色和定量PCR分析ERCC6在NSCLC中的表达。Celigo 细胞计数、集落形成、流式细胞术、伤口愈合和 transwell 测定用于评估 ERCC6 敲低对 NSCLC 细胞增殖、凋亡和迁移的影响。通过建立异种移植模型评估ERCC6敲低对NSCLC细胞成瘤能力的影响。ERCC6在NSCLC肿瘤组织和细胞系中高表达，ERCC6 的高表达与总体生存率差显着相关。此外，ERCC6 敲低显着抑制细胞增殖、集落形成和迁移，同时在体外加速 NSCLC 细胞的细胞凋亡。此外，ERCC6 敲低抑制体内肿瘤生长。进一步的研究证实，ERCC6 敲低减弱了 Bcl-w、CCND1 和 c-Myc 的表达水平。总之，这些数据揭示了 ERCC6 在 NSCLC 进展中的重要作用，ERCC6 有望成为 NSCLC 治疗的新靶点。进一步的研究证实，ERCC6 敲低减弱了 Bcl-w、CCND1 和 c-Myc 的表达水平。总之，这些数据揭示了 ERCC6 在 NSCLC 进展中的重要作用，ERCC6 有望成为 NSCLC 治疗的新靶点。进一步的研究证实，ERCC6 敲低减弱了 Bcl-w、CCND1 和 c-Myc 的表达水平。总之，这些数据揭示了 ERCC6 在 NSCLC 进展中的主要作用，ERCC6 有望成为 NSCLC 治疗的新靶点。